Bipolar disorder is a condition affecting an individual’s affective states (mood). The different flavors of bipolar disorder have in common that there are alterations in mood between above ‘normal’ (hypomania, mania) and normal or below normal (melancholia, depression). The other important mood disorders are the various types of depression, while mania without episodes of depressions is a rarity. The first line treatment of choice in cases of bipolar disorder is medication. However, in the long run psychotherapy has shown to be successful in making the condition more manageable for individuals suffering from it. This article presents the different types of medication used for bipolar disorder.
Keywords: bipolar disorder, medication, therapy
For the full article please click on the following link:
Bipolar Disorder and Medication (2)
Cannabis is the most widely used illicit drug in the United States. Social and policy trends, as reflected in national surveys and state legislation, demonstrate increasing acceptance and use of cannabis with decreasing perception of harm, which may lead to an increased occurrence of cannabis use disorder. As with other substance use disorders, cannabis use disorder commonly co-occurs with non-substance-related psychiatric disorders, putting all psychiatrists at the frontlines to identify and treat patients with this disorder.
There are no FDA-approved medications for the treatment of cannabis use disorder, and few individuals who receive behavioral interventions are able to achieve sustained abstinence (Gates et al., 2016). However, several clinical trials in adults provide evidence for the off-label use of medications in the treatment of the disorder.
The current strategies for the off-label treatment of cannabis use disorder target withdrawal symptoms, aim to initiate abstinence and prevent relapse or reduce use, and treat psychiatric comorbidity and symptoms that may contribute to cannabis use. Here, we focus on the evidence supporting these key strategies. …
See full article at PsychiatricNews at http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2016.PP12a1